Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
Taleghani Hospital, Urmia University of Medical Sciences, Urmia, Iran.
J Cosmet Dermatol. 2024 Jun;23(6):2103-2108. doi: 10.1111/jocd.16227. Epub 2024 Feb 13.
Treatment of vitiligo is still a big challenge for dermatologists. The efficacy of statins in the treatment of vitiligo is controversial.
We studied possible therapeutic effect of topical 1% niosomal atorvastatin ointment combined with topical 0.1% tacrolimus in treatment of non-segmental vitiligo.
This is a triple blind, pilot, randomized placebo-controlled trial (RCT) that was performed in dermatology clinic. All the patients used topical 0.1% tacrolimus cream twice daily (BD). Moreover, the intervention group participants used topical 1% niosomal atorvastatin ointment, and control group participants were prescribed placebo ointment, BD. Patients were evaluated using vitiligo area surface index (VASI) score and patients' satisfaction at baseline and after 3 months treatment.
The mean patient satisfaction in the intervention and control groups were 5 ± 1.4 and 3.5 ± 1.9; the difference between groups was not statistically significant (p = 0.9). We found statistically significant difference in VASI score before and after treatment in both intervention and control groups (p = 0.01 and p = 0.03, respectively). However, comparison of the VASI score between groups was not statistically significant (p = 0.62). We also found no significant correlation between VASI score and other variables.
The result of this study indicates that adding of niosomal atorvastatin 1% ointment to topical calcineurin inhibitor has no additional effect on non-segmental type of vitiligo. Further large studies with different combinations are recommended before any conclusive result can be concluded on efficacy of statins in vitiligo.
治疗白癜风仍然是皮肤科医生面临的一大挑战。他汀类药物治疗白癜风的疗效存在争议。
我们研究了局部 1% 纳米脂质体阿托伐他汀软膏联合局部 0.1% 他克莫司治疗非节段性白癜风的可能治疗效果。
这是一项在皮肤科诊所进行的三盲、先导、随机安慰剂对照试验（RCT）。所有患者均每日两次使用局部 0.1% 他克莫司乳膏（BD）。此外，干预组患者使用局部 1% 纳米脂质体阿托伐他汀软膏，对照组患者给予安慰剂软膏，BD。在基线和治疗 3 个月后，使用白癜风面积表面指数（VASI）评分和患者满意度评估患者。
干预组和对照组患者的平均满意度分别为 5±1.4 和 3.5±1.9；组间差异无统计学意义（p=0.9）。我们发现干预组和对照组治疗前后 VASI 评分均有统计学差异（p=0.01 和 p=0.03）。然而，组间 VASI 评分比较无统计学意义（p=0.62）。我们还发现 VASI 评分与其他变量之间无显著相关性。
本研究结果表明，在局部钙调神经磷酸酶抑制剂中添加 1% 纳米脂质体阿托伐他汀对非节段性白癜风没有额外的疗效。在得出他汀类药物治疗白癜风疗效的结论之前，建议进行更多不同组合的大型研究。
